JP2024531259A5 - - Google Patents

Info

Publication number
JP2024531259A5
JP2024531259A5 JP2024508793A JP2024508793A JP2024531259A5 JP 2024531259 A5 JP2024531259 A5 JP 2024531259A5 JP 2024508793 A JP2024508793 A JP 2024508793A JP 2024508793 A JP2024508793 A JP 2024508793A JP 2024531259 A5 JP2024531259 A5 JP 2024531259A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
formula
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024508793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531259A (ja
JP7804370B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074908 external-priority patent/WO2023019244A1/en
Publication of JP2024531259A publication Critical patent/JP2024531259A/ja
Publication of JP2024531259A5 publication Critical patent/JP2024531259A5/ja
Priority to JP2025284521A priority Critical patent/JP2026042844A/ja
Application granted granted Critical
Publication of JP7804370B2 publication Critical patent/JP7804370B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024508793A 2021-08-13 2022-08-12 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法 Active JP7804370B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025284521A JP2026042844A (ja) 2021-08-13 2025-12-26 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163233039P 2021-08-13 2021-08-13
US63/233,039 2021-08-13
PCT/US2022/074908 WO2023019244A1 (en) 2021-08-13 2022-08-12 Compositions and methods for reducing immune intolerance and treating autoimmune disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025284521A Division JP2026042844A (ja) 2021-08-13 2025-12-26 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2024531259A JP2024531259A (ja) 2024-08-29
JP2024531259A5 true JP2024531259A5 (cg-RX-API-DMAC10.html) 2025-08-20
JP7804370B2 JP7804370B2 (ja) 2026-01-22

Family

ID=83151645

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024508793A Active JP7804370B2 (ja) 2021-08-13 2022-08-12 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法
JP2025284521A Pending JP2026042844A (ja) 2021-08-13 2025-12-26 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025284521A Pending JP2026042844A (ja) 2021-08-13 2025-12-26 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法

Country Status (7)

Country Link
US (4) US11648225B2 (cg-RX-API-DMAC10.html)
EP (1) EP4384505A1 (cg-RX-API-DMAC10.html)
JP (2) JP7804370B2 (cg-RX-API-DMAC10.html)
KR (1) KR102985637B1 (cg-RX-API-DMAC10.html)
CN (1) CN117940407A (cg-RX-API-DMAC10.html)
CA (1) CA3228242A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023019244A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12697320B2 (en) 2021-01-29 2026-08-04 Tim Therapeutics, Inc. Tartaric acid analogs and uses thereof
CN117940407A (zh) 2021-08-13 2024-04-26 Lapix生物治疗股份有限公司 降低免疫不耐受和治疗自身免疫病症的组合物和方法
US20260144239A1 (en) 2022-10-25 2026-05-28 Lapix Therapeutics, Inc. Immune Cell-Engrafted Non-Human Animals and Non-Human Animal Models
WO2024118602A1 (en) 2022-11-29 2024-06-06 Lapix Therapeutics, Inc. Compositions and methods for reducing immune intolerance and treating autoimmune disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US6004955A (en) 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
US20040072802A1 (en) * 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
DE10359829A1 (de) 2003-12-12 2005-07-21 Salama, Zoser B., Dr.Rer.Nat. Verwendung von CHP als Inhibitor von Glutathion-S-Transferasen und Kollagen IV
JP6783652B2 (ja) 2013-09-24 2020-11-11 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク 抗原特異的免疫原性を低減するための組成物及び方法
JP6699011B2 (ja) * 2014-07-04 2020-05-27 国立大学法人 東京大学 脂肪酸サロゲートを含むリゾホスファチジルセリン誘導体
ES2952038T3 (es) 2016-04-05 2023-10-26 Univ New York State Res Found Composiciones que contienen fosfoserina para la inducción de la tolerancia inmune
EP3481866B1 (en) 2016-07-06 2024-07-24 Bristol-Myers Squibb Company Combination of tim-4 antagonist and pd-1 antagonist and methods of use
AU2018323462A1 (en) 2017-08-28 2020-03-26 Bristol-Myers Squibb Company TIM-3 antagonists for the treatment and diagnosis of cancers
US20240173389A1 (en) 2021-03-11 2024-05-30 Lapix Therapeutics, Inc. Compositions and Methods For Reducing Immune Intolerance
EP4384495A1 (en) 2021-08-13 2024-06-19 Lapix Therapeutics, Inc. Compositions and methods for reducing immune intolerance and treating autoimmune disorders
CN117940407A (zh) 2021-08-13 2024-04-26 Lapix生物治疗股份有限公司 降低免疫不耐受和治疗自身免疫病症的组合物和方法

Similar Documents

Publication Publication Date Title
JP2022508705A5 (cg-RX-API-DMAC10.html)
US10232058B2 (en) Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
US9216956B2 (en) Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
JP2020511943A5 (cg-RX-API-DMAC10.html)
TW201202262A (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
JP2016505019A5 (cg-RX-API-DMAC10.html)
JP2019504087A5 (cg-RX-API-DMAC10.html)
JP2018519834A5 (cg-RX-API-DMAC10.html)
JP2013542963A5 (cg-RX-API-DMAC10.html)
JP2024522183A5 (cg-RX-API-DMAC10.html)
CA3176191A1 (en) Treatment of proliferative diseases of the cns
CN117940407A (zh) 降低免疫不耐受和治疗自身免疫病症的组合物和方法
JP2024504366A5 (cg-RX-API-DMAC10.html)
US20220002730A1 (en) Oligonucleotide inhibitors of nuclear factor kappa-light-chain-enhancer of activated b cells and the uses thereof
Rietsema Unexpected recovery of moderate cognitive impairment on treatment with oral methylcobalamin
US20260083671A1 (en) Stabilized formulation comprising recombinant stabilized galectin 9 protein
RU2024105920A (ru) Композиции и способы снижения иммунной непереносимости и лечения аутоиммунных расстройств
US20170304433A1 (en) Vaccine compositions and methods of use to treat neonatal subjects
US20230119606A1 (en) Immune cell modulators
JP2024546654A5 (cg-RX-API-DMAC10.html)
ES2983628T3 (es) Compuestos
JP2023545788A (ja) ジヒドロオロト酸デヒドロゲナーゼ(dhodh)阻害剤による自己免疫疾患の治療
BRPI0610351A2 (pt) uso de compostos de triazina e medicamentos compreendendo os mesmos
RU2019145035A (ru) Новые ингибиторы cdk8/19
JP2021528479A5 (cg-RX-API-DMAC10.html)